A metro Atlanta woman has filed a negligence lawsuit alleging that a mislabeled tissue sample led doctors to tell her she had an aggressive uterine cancer she never had, and that she underwent a full hysterectomy as a result.
Cassandra Barksdale, who was 43 at the time of the surgery, filed the complaint in the State Court of Clayton County, Georgia, on August 4 against Kaiser Foundation Health Plan of Georgia, Kaiser Foundation Health Plan, Kaiser Permanente Insurance Co. and a senior laboratory information analyst. The allegations have not been proven in court, and no defendant has been found liable.
The case is drawing attention beyond one courtroom because the alleged failure sits at a step in medicine that patients never see and rarely think about: the moment a specimen is labeled.
The Sequence Described in the Complaint
According to the lawsuit, Barksdale sought care for uterine fibroids and abnormal bleeding at a Kaiser Permanente medical center in Jonesboro in early 2025. She was referred to another obstetrician and underwent an endometrial tissue biopsy in March of that year. The specimen was identified and labeled by Kaiser laboratory staff, then sent to an outside laboratory for testing.
The complaint alleges that another patient's tissue sample was labeled as hers. The result came back positive for an aggressive, high-grade endometrial cancer.
A subsequent CT scan, the suit says, showed no evidence of cancer. Barksdale was nonetheless referred to a specialist at Northside Hospital Atlanta, and a physician recommended a total hysterectomy with removal of the ovaries and lymph node biopsies based on the earlier imaging and pathology records. The surgery took place in May 2025 and removed her cervix, uterus, fallopian tubes, ovaries and four lymph nodes. She was told she would receive instructions about chemotherapy.
Testing of Barksdale's own tissue after the operation found no cancer or malignancy in the endometrial cavity, according to the complaint. Months later, in September, DNA analysis established that the specimen showing aggressive cancer had belonged to a different patient. Barksdale has said the intervening months, spent believing she had a terminal illness, sent her into a deep depression.
Kaiser Permanente, in a statement, said "Ms. Barksdale should not have experienced this," described having trained staff and thorough processes intended to prevent such errors, and said it took immediate steps after the incident to ensure it could not happen again. The organization said it is committed to working with Barksdale and her counsel to resolve the matter. The suit seeks a jury trial and damages to be determined at trial.
Specimen Identification Is the Quiet Foundation of a Diagnosis
Every cancer diagnosis rests on a chain of custody. A clinician collects tissue, someone labels the container, the specimen travels to a laboratory, a pathologist examines the slide, and a report returns bearing a patient's name.
Errors at the labeling step are consequential precisely because nothing downstream detects them. A pathologist reading a slide correctly identifies what is on it. If the wrong name is attached, the interpretation is accurate, and the diagnosis is still wrong.
How often this happens is not well established. The Associated Press reported that it is unclear how frequently pathology samples are mislabeled or mixed up, while noting a similar suit filed by an Ohio woman over a 2019 biopsy error that led to a lung cancer misdiagnosis and unneeded surgery. Laboratories have adopted defenses against the failure, including barcode-based labeling, two-person verification at collection, point-of-care printing that generates the label at the patient's side, and DNA identity testing when a result does not fit the clinical picture.
The lawsuit's co-counsel, Roderick Edmond, a physician and attorney, told reporters that the firm's review of records to date points to the handling of the specimen by hospital laboratory staff rather than to the outside testing laboratory or the physicians who acted on the result. He called it "a bizarre case" given the technology available in modern laboratories. That remains one side's characterization of an unresolved dispute.
The Consequence Was Surgical and Permanent
The clinical stakes in this category of error are not abstract. A total hysterectomy with removal of the ovaries induces immediate surgical menopause in a premenopausal patient, ending fertility and triggering hormonal changes that would otherwise arrive gradually over years. Barksdale, a mother of two, has said she was not finished having children.
There is a second patient in this story. The complaint states that the specimen showing aggressive endometrial cancer belonged to another woman who did have the disease. Privacy law means nothing further is public about her, including when she learned her result. That is among the most important unresolved elements of the case.
For readers, the useful takeaway is not fear of biopsies. Endometrial biopsy is the appropriate response to abnormal uterine bleeding, and delayed evaluation carries far greater aggregate risk than a rare labeling error. The takeaway is that patients may ask questions when pieces of a diagnosis do not fit together.
Reasonable questions include asking to see the pathology report itself rather than a verbal summary, confirming that the name, date of birth and collection date on the report match, asking the treating physician to explain any discrepancy between imaging and pathology, and requesting a second pathology opinion before an irreversible operation. Many insurers cover second opinions, and academic medical centers commonly offer slide review services. Patients should not delay urgent cancer treatment while seeking one, and these are questions for a clinician rather than a substitute for medical advice.
An Unresolved Case with No Findings Yet
Nothing in the complaint has been tested through discovery or trial. Kaiser Permanente has not conceded liability, and its statement acknowledged the incident without accepting the legal claims. How the alleged mix-up occurred has not been publicly established.
The next milestones are the defendants' formal answer to the complaint, any motions to dismiss, and whether the parties pursue resolution outside court, which the health system's statement suggested it is open to doing. Whether Georgia regulators or accreditation bodies review the laboratory's specimen handling has not been announced.
The confirmed facts are that a lawsuit was filed, that DNA analysis established the cancerous specimen belonged to another patient, and that the health system has said the experience should not have happened. The most affected group is patients facing major surgery based on a single pathology result. The reasonable action is asking to review the report and, where time allows, seeking a second pathology opinion. The central uncertainty is how the error occurred and who bears responsibility. MedicalDaily will follow the case as it proceeds.
Key Questions Answered
What does the lawsuit allege? It alleges that another patient's endometrial tissue sample was labeled as belonging to Cassandra Barksdale, producing a false diagnosis of aggressive uterine cancer that led to a total hysterectomy in May 2025. The claims have not been proven in court.
Has anyone been found liable? No. The complaint was filed in early August and no court has ruled on it. Kaiser Permanente has said the experience should not have happened and that it is committed to resolving the matter, without conceding the legal claims.
How can a labeling error survive the rest of the process? Because every later step depends on the label being correct. A pathologist accurately reports what is on the slide. If the wrong patient name is attached, the diagnosis is wrong even though the laboratory analysis is right.
How common are specimen mix-ups? The frequency is not well established, though similar cases have surfaced in litigation elsewhere. Laboratories use barcoding, two-person verification and DNA identity testing to reduce the risk.
What questions can a patient reasonably ask before major surgery? Ask to read the pathology report, confirm that the name, date of birth and collection date match, ask the physician to reconcile any conflict between imaging and pathology, and ask whether a second pathology opinion is appropriate before an irreversible procedure.
Should this discourage anyone from having a biopsy? No. Endometrial biopsy is the standard evaluation for abnormal uterine bleeding, and skipping it carries substantially greater risk than a rare labeling failure. Anyone with abnormal bleeding should be evaluated by a clinician.
What happens next in the case? The defendants will file a formal response, and the parties may pursue motions or an out-of-court resolution. No regulatory review of the laboratory's specimen handling has been publicly announced.
